These observations support the potential effectiveness of vidofludimus calcium in slowing disease progression in PMS and further substantiate its neuroprotective capabilities through the activation of ...
Analyst William Wood from B.Riley Financial reiterated a Buy rating on Immunic (IMUX – Research Report) and keeping the price target at ...
nuclear receptor related 1 (Nurr1) activator, vidofludimus calcium's (IMU-838) therapeutic potential in multiple sclerosis (MS). Key Insights Given the large stake in the stock by institutions, ...